385TiP - RIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease - Kenis, C.; Ponde, N.F.; Decoster, L.; de Azambuja, E.; Jerusalem, G.; Neven, P.; Dal Lago, L.; Denys, H.; Vuylsteke, P.; Duhoux, F.P.; Wildiers, H. (Annals of Oncology, 2019)